|

Lung Cancer Clinical Trials in Michigan

175 recruiting studies across 65 cities

All Trials in Michigan

Phase
Trial Phase Location
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerPhase 3Adrian
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])Phase 3Adrian
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics—Alma
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection—Alma
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerPhase 2/3Alma
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 ChangePhase 2Alma
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS MutationsPhase 1/2Ann Arbor
A Phase 1/1b Study of IAM1363 in HER2 CancersPhase 1Ann Arbor
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsPhase 1/2Ann Arbor
A Phase I/II Study of VLS-1488 in Subjects With Advanced CancerPhase 1/2Ann Arbor
A Registry for People With Lung Cancer—Ann Arbor
A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer PatientsN/AAnn Arbor
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal MesotheliomaPhase 2Ann Arbor
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Phase 2Ann Arbor
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)Phase 2Ann Arbor
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerPhase 3Ann Arbor
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)Phase 1Ann Arbor
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)Phase 2Ann Arbor
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)Phase 2Ann Arbor
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsPhase 1/2Ann Arbor
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After TreatmentPhase 2Ann Arbor
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasPhase 1/2Ann Arbor
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-KitPhase 1Ann Arbor
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionPhase 2/3Ann Arbor
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid TumorsPhase 1/2Ann Arbor
Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLCPhase 1/2Ann Arbor
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1Phase 3Ann Arbor
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)Phase 2Ann Arbor
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard ChemoimmunotherapyPhase 3Ann Arbor
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung CancerPhase 1/2Ann Arbor
Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the LungPhase 3Ann Arbor
Gilteritinib for the Treatment of ALK NSCLCPhase 1Ann Arbor
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT TrialPhase 3Ann Arbor
Prediction Augmented Screening InitiativeN/AAnn Arbor
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical IllnessesPhase 2Ann Arbor
Repositioning Immunotherapy in VetArans With Lung CancerPhase 2Ann Arbor
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry—Ann Arbor
Safety and Durability of Sirolimus for Treatment of LAM—Ann Arbor
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic TumorsPhase 1Ann Arbor
Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver MetastasesPhase 2Ann Arbor
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)Phase 3Ann Arbor
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)Phase 1Ann Arbor
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)Phase 2Ann Arbor
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)Phase 2Ann Arbor
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerPhase 3Ann Arbor
The SEQUENCE TrialN/AAnn Arbor
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With OsteosarcomaPhase 3Ann Arbor
University of Michigan COPD Identification Through Lung Cancer Screening Cohort Study - MAP2—Ann Arbor
Veterans Affairs Lung Cancer Surgery Or Stereotactic RadiotherapyN/AAnn Arbor
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialPhase 3Battle Creek
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC TrialPhase 3Battle Creek
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)Phase 2/3Brighton
Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)Phase 2Brighton
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM StudyPhase 2Brighton
The Vanguard Study: Testing a New Way to Screen for CancerN/ABrownstown
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsPhase 1/2Dearborn
A Study of IBI363 in Subjects with Advanced Solid MalignanciesPhase 2Dearborn
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor ResectionPhase 3Dearborn
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL CancerPhase 2Dearborn
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic AlterationsPhase 3Dearborn
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant TumorsPhase 1/2Detroit
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)Phase 1/2Detroit
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)Phase 3Detroit
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid TumorsPhase 1/2Detroit
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsPhase 2Detroit
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)Phase 1/2Detroit
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the LungsPhase 1/2Detroit
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid TumorsPhase 1/2Detroit
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid TumorsPhase 1/2Detroit
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)Phase 3Detroit
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung CancerPhase 2Detroit
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 MutationsPhase 1/2Detroit
A Study of DB-1310 in Advanced/Metastatic Solid TumorsPhase 1/2Detroit
A Study of DM005 in Patients With Advanced Solid TumorsPhase 1/2Detroit
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor MalignanciesPhase 1/2Detroit
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)Phase 1/2Detroit
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesPhase 1Detroit
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerPhase 3Detroit
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)Phase 2Detroit
A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsPhase 1Detroit
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung CancerPhase 1Detroit
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)Phase 3Detroit
A Study of ZL-1310 in Subjects With Small Cell Lung CancerPhase 1Detroit
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid TumorsPhase 1/2Detroit
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung CancerPhase 2Detroit
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung CancerPhase 1/2Detroit
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)Phase 3Detroit
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung CancerPhase 2Detroit
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor TypesPhase 1/2Detroit
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.Phase 4Detroit
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung CancerPhase 2Detroit
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsPhase 1Detroit
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)Phase 1/2Detroit
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian CancerPhase 1/2Detroit
First-in-human Study of Interferon-y PET Imaging to Assess Response to ImmunotherapyPhase 1Detroit
JAB-2485 Activity in Adult Patients With Advanced Solid TumorsPhase 1/2Detroit
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung CancerPhase 3Detroit
KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsPhase 1Detroit
MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung CancerPhase 2Detroit
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLCPhase 3Detroit
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid TumorsPhase 1Detroit
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung CancerPhase 1Detroit
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid TumorsPhase 1Detroit
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung CancerPhase 1Detroit
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid TumorsPhase 1/2Detroit
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic AlterationsPhase 3Detroit
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung CancerPhase 3Detroit
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLCPhase 1Detroit
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT—Detroit
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)Phase 1/2Detroit
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsPhase 1/2Detroit
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)Phase 1/2Detroit
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerPhase 3Detroit
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCPhase 1/2Detroit
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene AbnormalitiesPhase 1/2Detroit
Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung CancerPhase 2Detroit
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsPhase 1Detroit
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsPhase 1/2Detroit
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsPhase 3Detroit
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM TrialPhase 3Detroit
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)Phase 1/2Detroit
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid TumorsPhase 1Farmington Hills
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid TumorsPhase 1/2Farmington Hills
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerPhase 3Farmington Hills
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)Phase 3Farmington Hills
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)Phase 3Farmington Hills
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsPhase 1/2Grand Rapids
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCPhase 3Grand Rapids
A Multicenter Study in Bronchoscopy Combining Stimulated Raman Histology With Artificial Intelligence for Rapid Lung Cancer Detection - The ON-SITE Study—Grand Rapids
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid TumorsPhase 1Grand Rapids
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell CarcinomasPhase 1Grand Rapids
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung CancerPhase 1/2Grand Rapids
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsPhase 1Grand Rapids
A Study of MGC026 in Participants With Advanced Solid TumorsPhase 1Grand Rapids
A Study of MT-4561 in Patients With Various Advanced Solid TumorsPhase 1/2Grand Rapids
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid TumorsPhase 1/2Grand Rapids
A Study of SGN-CEACAM5C in Adults With Advanced Solid TumorsPhase 1Grand Rapids
A Study of Sofe-M in Participants With Selected Advanced Solid TumorsPhase 1Grand Rapids
A Study of ZW251 in Participants With Advanced Solid TumorsPhase 1Grand Rapids
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid TumorsPhase 1Grand Rapids
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid TumorsPhase 1Grand Rapids
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid TumorsPhase 1Grand Rapids
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous TumorsPhase 1Grand Rapids
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung CancerPhase 3Grand Rapids
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid TumorsPhase 1Grand Rapids
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsPhase 1/2Grand Rapids
A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.Phase 1Grand Rapids
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid TumorsPhase 1Grand Rapids
CT-95 in Advanced Cancers Associated With Mesothelin ExpressionPhase 1Grand Rapids
DBC-664 in Adult Patients With Solid TumorsPhase 1Grand Rapids
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia—Grand Rapids
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation—Grand Rapids
Pan-tumor MRD Study—Grand Rapids
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP DeletionPhase 1Grand Rapids
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid TumorsPhase 1Grand Rapids
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid TumorsPhase 1/2Grand Rapids
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive MalignanciesPhase 1/2Grand Rapids
Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)Phase 3Grand Rapids
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal CancersPhase 1Grand Rapids
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected SarcomasPhase 1/2Grand Rapids
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid TumorsPhase 1/2Grand Rapids
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid TumorsPhase 1Grand Rapids
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerPhase 1/2Grand Rapids
Study of CP-383 in Patients With Advanced or Metastatic Solid TumorsPhase 1/2Grand Rapids
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid TumorsPhase 1Grand Rapids
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab AdizutecanPhase 1Grand Rapids
Study to Assess GTAEXS617 in Participants With Advanced Solid TumorsPhase 1/2Grand Rapids
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsPhase 1/2Grand Rapids
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.Phase 3Grand Rapids
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%Phase 3Royal Oak
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid TumorsPhase 1Royal Oak
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung CancerPhase 3Saginaw
Empathic Communication Skills (ECS) TrainingN/ATraverse City
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Phase 3Ypsilanti
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]Phase 3Ypsilanti

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.